CdmoGen Co., Ltd.
Cheongju, South Korea
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
○ EMA GMP
○ MHRA GMP
Quick Facts: CdmoGen Co., Ltd.
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Cheongju, South Korea
- Modalities
- AAV, Lentiviral, Retroviral, mRNA, Cell Therapy (ex vivo gene-modified), Viral Vectors (general), Plasmid DNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About CdmoGen Co., Ltd.
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Retroviral, mRNA, Cell Therapy (ex vivo gene-modified), Viral Vectors (general), Plasmid DNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press1 articles
Broad modality coverage (7 modalities)
Recent News 1 articles
Therapeutic potential of AAV2-shmTOR gene therapy in reducing retinal inflammation and preserving endothelial Integrity in age-related macular degeneration - Nature
Frequently Asked Questions About CdmoGen Co., Ltd.
What is CdmoGen Co., Ltd.'s CDMO Signal Score?
CdmoGen Co., Ltd. has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating CdmoGen Co., Ltd. for a manufacturing program?
Use the free AI matchmaker to compare CdmoGen Co., Ltd. against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
Signal Score: 60.0
Plasmid DNA, AAV, Adenoviral, Lentiviral, Retroviral, mRNA, sgRNA, Exosome
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.1
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid
Lonza
Basel, Switzerland
Signal Score: 78.2
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein
Oxford Biomedica
Oxford, United Kingdom
Signal Score: 77.1
Lentiviral, AAV, Plasmid DNA